What Researchers Did
Researchers conducted a scoping review to summarize available studies on therapeutic agents for patients with post-acute sequelae of COVID-19 (PASC).
What They Found
Out of 413 identified studies, 39 were included, evaluating therapeutic agents such as hyperbaric oxygen, ivermectin, metformin, naltrexone, micronutrient supplements, antifibrotic agents, antiviral agents, and selective serotonin reuptake inhibitors (SSRIs).
Hyperbaric oxygen, antifibrotic agents, antiviral agents, and SSRIs showed promising results, though the heterogeneity of PASC symptoms made synthesizing findings challenging.
What This Means for Canadian Patients
Canadian patients experiencing PASC may benefit from the identified promising therapeutic options, including hyperbaric oxygen, antifibrotic agents, antiviral agents, and SSRIs.
However, due to the diverse nature of PASC symptoms, personalized treatment approaches and further targeted research are needed to effectively manage their condition.
Canadian Relevance
This study did not have a direct Canadian connection.
Study Limitations
A key limitation was the significant heterogeneity of PASC symptoms, which complicated the synthesis of findings for specific symptom-based outcomes across the reviewed studies.